I definitely wondered the same Epichemist, expect most things to fail in the TBI/CVA space. For mine the value of the company is the cholesterol program, and I’m just reassured to see they’re getting closer to this trial starting, that they redesigned it to see a efficacy signal in patients with high cholesterol. I mean would anyone really sell their shares based on the stroke study not having positive results?
I definitely wondered the same Epichemist, expect most things to...
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.003(4.05%) |
Mkt cap ! $13.45M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.5¢ | $8.064K | 105.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 53000 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 10715 | 1 |
View Market Depth
| Last trade - 11.15am 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
7.7¢ |
Change
0.003 ( 2.67 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 7.9¢ | 7.7¢ | 74653 | ||
| Last updated 12.00pm 05/06/2024 ? | |||||
| NYR (ASX) Chart |